Search
Close this search box.

Holafly partners with Valientes Colombia to support community-led initiatives and address the social impact of tourism

Partnership for Responsible Tourism in Colombia DUBLIN, May 27, 2026 (GLOBE NEWSWIRE) — As discussions about responsible travel move beyond sustainability toward real impact, Holafly, the global eSIM provider for travelers, announces a partnership with Valientes Colombia, a locally led organization that prevents exploitation and supports vulnerable communities through education

Elevate Your Strategy: Global Trading Competition Launch with Major Cash Prizes

EBC Financial Group initiates dual-track events across Asia and Africa, offering both risk-free simulated environments and high-stakes market showdowns to empower traders of all experience levels LONDON, May 26, 2026 (GLOBE NEWSWIRE) — EBC Financial Group (EBC), the World’s Best Broker according to World Finance, has launched two multimarket trading

Bitget Launches “Gold Fast or Go Home Challenge” for Gold CFD Trading

Bitget Launches “Gold Fast or Go Home Challenge” for Gold CFD Trading VICTORIA, Seychelles, May 20, 2026 (GLOBE NEWSWIRE) — Bitget, the world’s largest Universal Exchange (UEX), has launched the “Gold Fast or Go Home Challenge,” a global campaign built around faster access to gold CFD trading on the Bitget

Bitget Launches “Gold Fast or Go Home Challenge” for Gold CFD Trading

Bitget Launches “Gold Fast or Go Home Challenge” for Gold CFD Trading VICTORIA, Seychelles, May 20, 2026 (GLOBE NEWSWIRE) — Bitget, the world’s largest Universal Exchange (UEX), has launched the “Gold Fast or Go Home Challenge,” a global campaign built around faster access to gold CFD trading on the Bitget

Risen Pharma Announces Initiation of Phase 2 Clinical Trial of RP902 for Mild Cognitive Impairment Due to Alzheimer’s Disease

SHANGHAI, May 19, 2026 (GLOBE NEWSWIRE) — Risen Pharma, a clinical-stage biotech company focusing on the development and commercialization of high-need, patient-accessible therapeutics, today announced the initiation of a Phase 2 clinical study in China of RP902, an oral small-molecule drug developed to address significant unmet medical needs in patients